UGT1A6 and Seizure: A study of VPA monotherapy and stable control of epileptic seizures in patients with epilepsy showed that carriers of SNVs UGT1A6*3 (rs6759892; 19T>G), UGT1A6*5 (rs2070959; 541A>G) and UGT1A6*9 (rs1105879; 552A>C) had a reduction in blood levels of VPA therapeutic metabolites.